Viatris Inc. (NASDAQ: VTRS) today announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimo ...

Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and ...

Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human ...

The year is ending with a strong flow of clinical results, with Percheron Therapeutics due to release key trial data tomorrow ...

Liver fibrosis is characterized by the excessive accumulation of extracellular matrix components, leading to scarring and impaired liver function. Traditionally linked to viral infections, alcohol ...

Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for ...

Immune checkpoint blockades, or ICBs, have revolutionized treatment for various advanced cancers. However, their effectiveness has plateaued due to therapeutic resistance that renders ...

Monash University-led research is unlocking new ways for immunotherapy to better target cancer. Cancer immunotherapy has revolutionised treatment for patients, whereby the body’s own immune system is ...

The regulator HIF1α functions in a cancer-microenvironment that lacks oxygen, and it may be involved in resistance to immune ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing ...

To test their guards in a living organism, the researchers then took beta cells derived from stem cells and implanted them ...

But your account is considered open the moment your application is approved — regardless of whether you activate the card. Since opening a new account can have some impact on your credit score ...